Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

Table 3 Summary of the multivariable analyses of prognostic factors after propensity score matching

Variable	OS		DSS		DMFS		LRFS
Variable	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
IC regimen (PF vs. TPF)	0.581 (0.371–0.910)	0.018	0.543 (0.343–0.859)	0.009	0.551 (0.357–0.850)	0.007	1.179 (0.667–2.084)	0.572
Gender (male vs. female)	1.166 (0.679–2.004)	0.578	1.069 (0.613–1.861)	0.815	1.065 (0.623–1.818)	0.819	0.935 (0.450–1.939)	0.856
Age	1.026 (1.006–1.046)	0.010	1.024 (1.004–1.044)	0.017	1.013 (0.994–1.033)	0.173	1.014 (0.987–1.041)	0.308
Smoking (yes vs. no)	1.020 (0.616–1.687)	0.939	1.004 (0.604–1.667)	0.989	1.118 (0.685–1.823)	0.656	1.061 (0.555–2.028)	0.857
T stage (T1–2 vs. T3–4)	1.349 (0.866–2.101)	0.185	1.345 (0.863–2.096)	0.191	1.449 (1.056–1.987)	0.021	1.434 (0.752–2.733)	0.274
N stage (N0–1 vs. N2–3)	1.285 (0.975–1.693)	0.075	1.319 (0.995–1.748)	0.054	1.652 (1.278–2.134)	0.001	1.125 (0.778–1.627)	0.532
Clinical stage (III vs. IV)	2.193 (1.419–3.390)	0.001	2.277 (1.459–3.552)	0.001	1.137 (0.663–1.042)	0.667	0.891 (0.386–2.057)	0.787
Radiation technique (IMRT vs. 2D-CRT)	1.835 (1.153–2.919)	0.010	1.859 (1.159–2.982)	0.010	2.152 (1.370–3.380)	0.001	1.089 (0.550–2.156)	0.807

IC induction chemotherapy, TPF taxane, cisplatin and 5-fluorouracil, PF cisplatin and 5-fluorouracil, CDDP dose the cisplatin dose of concurrent chemotherapy, IMRT intensity-modulated radiotherapy, 2D-CRT two-dimensional radiotherapy, RT radiotherapy, HR hazard ratio

ISSN: 2523-3548